Detalles de la búsqueda
1.
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
Future Oncol
; 15(12): 1363-1383, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30758227
2.
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Lancet Oncol
; 15(2): 143-55, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24411639
3.
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet Respir Med
; 7(7): 569-580, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31103412
4.
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer.
ESMO Open
; 2(1): e000102, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28761724
5.
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
J Clin Oncol
; 35(31): 3591-3600, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28892431
6.
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Lung Cancer
; 102: 65-73, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27987591
7.
BIBF1120 (Vargatef) Inhibits Preretinal Neovascularization and Enhances Normal Vascularization in a Model of Vasoproliferative Retinopathy.
Invest Ophthalmol Vis Sci
; 56(13): 7897-907, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26670826
8.
Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
Lung Cancer
; 90(2): 267-73, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26415992
9.
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
Eur J Cancer
; 51(3): 317-26, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25534294
10.
Response to 'Dai W et al. Am J Cancer Res 2015;5(10):3270-3275' from the makers of nintedanib.
Am J Cancer Res
; 6(7): 1547-8, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27508096
11.
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Cancer
; 115(12): 2617-29, 2009 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19382200
12.
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
J Clin Oncol
; 25(30): 4779-86, 2007 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-17947725
13.
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
J Clin Oncol
; 26(4): 689-90, 2008 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18235136
Resultados
1 -
13
de 13
1
Próxima >
>>